Pharmaceuticals News and Research

RSS

Omnicare second-quarter earnings per diluted share decrease to 18 cents

Omnicare, Inc., one of the nation's leading providers of pharmaceutical care for the elderly, reported today financial results for its second quarter ended June 30, 2010.

7 Aug 2010

BMS to join ranks of AIDS drug companies to offer price concessions

Bristol-Myers Squibb will soon announce an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide. The agreement, with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors, is expected to be announced any day. BMS has been the target of a sustained advocacy campaign led by AHF over its pricing of its key AIDS drug Reyataz.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Results from a randomized study with Zyclara following cryotherapy in the treatment of actinic keratoses (AK) demonstrated Zyclara complemented the effectiveness of cryosurgery in reducing total AK count and achieving complete clearance of AK, according to data presented at the American Academy of Dermatology Summer Academy Meeting 2010 (Summer AAD), August 4 - 8.

7 Aug 2010

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its second quarter ended June 30, 2010.

7 Aug 2010

U.S. TSA designates BioStorage Technologies as Certified Cargo Screening Facility

BioStorage Technologies, a global leader in sample management and cold-chain logistics for the pharma and biotech industries, has recently been approved as a Certified Cargo Screening Facility (CCSF) by the U.S. Transportation Security Administration (TSA). The designation establishes BioStorage Technologies as one of the few sample management providers to achieve this clearance level, which allows the company to pre-screen shipments at its facility, thereby avoiding possible screening delays at the airport.

7 Aug 2010

ReSearch Pharmaceutical reports 32.9% in 2010 second quarter service revenues

ReSearch Pharmaceutical Services, Inc., a leading provider of integrated clinical development outsourcing solutions to the biopharmaceutical industry, announces its results for the three and six months ended June 30, 2010. These statements include unaudited comparative results for RPS for the three and six months ended June 30, 2009.

7 Aug 2010

Bloomberg Businessweek explores growing trend in pharma to license, donate HIV drugs

"Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines … in poor countries, lately have been slashing prices and licensing their drugs for free or nominal cost to nonprofits or local manufacturers in the developing world," Bloomberg BusinessWeek writes in an analysis piece that examines how this trend, combined with a growing capability among aid agencies to distribute drugs, has the potential to increase access to HIV/AIDS drugs worldwide.

7 Aug 2010

FDA confirms Advisory Committee meeting date for lorcaserin NDA review

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

7 Aug 2010

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes, Inc. today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010.

7 Aug 2010

Cornerstone announces ANDA filing for generic Tussionex

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that its product candidate CRTX-067 is an ANDA filing for a generic 10 mg chlorpheniramine polistirex/8 mg hydrocodone polistirex suspension product that will be a generic substitute for the product currently sold under the Tussionex brand name by UCB, Inc.

7 Aug 2010

Cyclacel second-quarter net loss decreases to $6.5 million

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.

7 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Arena Pharmaceuticals to sell common stock shares to Deerfield Management

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell a total of 8,955,224 shares of its common stock, at a price of $6.70 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization. Arena expects to receive gross proceeds, before expenses, of approximately $60 million. The closing of the offering is expected to take place on or before August 10, 2010.

7 Aug 2010

Catalyst announces $1.5 million registered direct offering

Catalyst Pharmaceutical Partners, Inc. today announced that it has entered into definitive agreements to sell 1,351,352 shares of its common stock at a price per share of $1.11 pursuant to a registered direct offering to two large mutual funds, representing gross proceeds of $1.5 million.

7 Aug 2010

Kids v Cancer applauds Senators for Creating Hope Act of 2010

Kids v Cancer applauds Senators Sam Brownback (R-KS), Sherrod Brown (D-OH), and Al Franken (D-MN) for their dedication to curing childhood diseases and supporting the bipartisan "Creating Hope Act of 2010."

7 Aug 2010

Bradmer second-quarter net loss decreases to US$161,000

Bradmer Pharmaceuticals Inc. today announced its 2010 second quarter financial results.

7 Aug 2010

Synthetech first-quarter fiscal 2011 revenue decreases 56% to $2.0 million

Synthetech, Inc. today announced financial results for the first quarter of fiscal 2011, which ended June 30, 2010. Revenue for the quarter was $2.0 million, a 56% decrease compared to revenue of $4.7 million in the first quarter of fiscal 2010. The operating loss for the current quarter was $727,000, compared to operating income of $1.0 million for the same period last year. The net loss for the current quarter was $763,000, or $0.05 per basic share, compared to last year's first quarter net income of $969,000, or $0.07 per basic share.

7 Aug 2010

FDA approves Lannett's ANDA for Ondansetron Injection

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Ondansetron Injection, USP, 2 mg/mL, Single-Dose Vials. Ondansetron Injection, USP, 2 mg/mL is the generic version of GlaxoSmithKline's Zofran Injection, 2 mg/mL.

7 Aug 2010

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion for RELISTOR (methylnaltrexone bromide) subcutaneous injection in pre-filled syringes.

7 Aug 2010